TD Cowen Downgrades Aadi Bioscience to Hold
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Boris Peaker has downgraded Aadi Bioscience from Buy to Hold, indicating a more cautious outlook on the stock.

August 21, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen analyst Boris Peaker has downgraded Aadi Bioscience from Buy to Hold, suggesting a more cautious stance on the stock.
The downgrade from Buy to Hold by a reputable analyst like Boris Peaker at TD Cowen suggests a less optimistic view on Aadi Bioscience's short-term performance. This could lead to a negative impact on the stock price as investors may adjust their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100